Tapentadol results in less deterioration of gastrointestinal function and symptoms than standard opioid therapy in healthy male volunteers.
colon
constipation
motility
opioid
Journal
Neurogastroenterology and motility
ISSN: 1365-2982
Titre abrégé: Neurogastroenterol Motil
Pays: England
ID NLM: 9432572
Informations de publication
Date de publication:
11 2021
11 2021
Historique:
revised:
17
02
2021
received:
28
10
2020
accepted:
09
03
2021
pubmed:
30
5
2021
medline:
4
3
2022
entrez:
29
5
2021
Statut:
ppublish
Résumé
Tapentadol is a combined opioid agonist and norepinephrine reuptake inhibitor with fewer gastrointestinal side effects at equianalgesic doses compared with classical strong opioids. Previous studies on tapentadol have included multi-morbid patients in whom confounders exclude detailed assessment of the mechanistic effects and strict comparison with other opioids or placebo. This study aimed at investigating the effects of tapentadol and oxycodone on gastrointestinal motility and gastrointestinal side effects. 21 healthy males participated in a randomized, double-blind, placebo-controlled, crossover study. Tapentadol (50 mg twice daily), oxycodone (10 mg twice daily), or placebo tablets were administered for 14 days. Segmental gastrointestinal transit times and colonic motility parameters were measured with electromagnetic capsules. Gastrointestinal side effects were assessed using questionnaires. During dosing with tapentadol, gastrointestinal side effects and motility parameters were on placebo level. Compared with tapentadol, oxycodone increased whole gut transit time by 17.9 hours (p = .015) and rectosigmoid transit time by 6.5 hours (p = .005). Compared with tapentadol, oxycodone also reduced long, fast antegrade colonic movements (p = .001). In comparison with placebo, oxycodone prolonged whole gut transit time by 31.6 hours, (p < .001). Moreover, less long, fast antegrade colonic movements (p = .002) were observed during oxycodone. For oxycodone only, slow colonic movements were associated with gastrointestinal side effects. In this mechanistic study, tapentadol caused significantly less colonic dysmotility and gastrointestinal side effects as compared with oxycodone in equianalgesic doses.
Sections du résumé
BACKGROUND
Tapentadol is a combined opioid agonist and norepinephrine reuptake inhibitor with fewer gastrointestinal side effects at equianalgesic doses compared with classical strong opioids. Previous studies on tapentadol have included multi-morbid patients in whom confounders exclude detailed assessment of the mechanistic effects and strict comparison with other opioids or placebo. This study aimed at investigating the effects of tapentadol and oxycodone on gastrointestinal motility and gastrointestinal side effects.
METHODS
21 healthy males participated in a randomized, double-blind, placebo-controlled, crossover study. Tapentadol (50 mg twice daily), oxycodone (10 mg twice daily), or placebo tablets were administered for 14 days. Segmental gastrointestinal transit times and colonic motility parameters were measured with electromagnetic capsules. Gastrointestinal side effects were assessed using questionnaires.
KEY RESULTS
During dosing with tapentadol, gastrointestinal side effects and motility parameters were on placebo level. Compared with tapentadol, oxycodone increased whole gut transit time by 17.9 hours (p = .015) and rectosigmoid transit time by 6.5 hours (p = .005). Compared with tapentadol, oxycodone also reduced long, fast antegrade colonic movements (p = .001). In comparison with placebo, oxycodone prolonged whole gut transit time by 31.6 hours, (p < .001). Moreover, less long, fast antegrade colonic movements (p = .002) were observed during oxycodone. For oxycodone only, slow colonic movements were associated with gastrointestinal side effects.
CONCLUSIONS & INFERENCES
In this mechanistic study, tapentadol caused significantly less colonic dysmotility and gastrointestinal side effects as compared with oxycodone in equianalgesic doses.
Substances chimiques
Adrenergic Uptake Inhibitors
0
Analgesics, Opioid
0
Oxycodone
CD35PMG570
Tapentadol
H8A007M585
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14131Informations de copyright
© 2021 John Wiley & Sons Ltd.
Références
Rauck RL, Hong KJ, North J. Opioid-induced constipation survey in patients with chronic noncancer pain. Pain Pract. 2017;17(3):329-335.
Christensen HN, Olsson U, From J, Breivik H. Opioid-induced constipation, use of laxatives, and health-related quality of life. Scand J Pain. 2016;11(1):104-110.
Coyne KS, Margolis MK, Yeomans K, et al. Opioid-induced constipation among patients with chronic noncancer pain in the United States, Canada, Germany, and the United Kingdom: Laxative use, response, and symptom burden over time. Pain Med. 2015;16(8):1551-1565.
Glare P, Walsh D, Sheehan D. The adverse effects of morphine: a prospective survey of common symptoms during repeated dosing for chronic cancer pain. Am J Hosp Palliat Care. 2006;23(3):229-235.
Farmer AD, Holt CB, Downes TJ, Ruggeri E, Del Vecchio S, De Giorgio R. Pathophysiology, diagnosis, and management of opioid-induced constipation. Lancet Gastroenterol Hepatol. 2018;3(3):203-212.
Tzschentke TM, Christoph T, Kögel BY. The Mu-opioid receptor agonist/noradrenaline reuptake inhibition (MOR-NRI) concept in analgesia: The case of tapentadol. CNS Drugs. 2014;28(4):319-329.
Meng Z, Yu J, Acuff M, et al. Tolerability of opioid analgesia for chronic pain: a network meta-analysis. Sci Rep. 2017;7(1):1995.
Daniels SE, Upmalis D, Okamoto A, Lange C, Häeussler J. A randomized, double-blind, phase III study comparing multiple doses of tapentadol IR, oxycodone IR, and placebo for postoperative (bunionectomy) pain. Curr Med Res Opin. 2009;25(3):765-776.
Jeong ID, Camilleri M, Shin A, et al. A randomised, placebo-controlled trial comparing the effects of tapentadol and oxycodone on gastrointestinal and colonic transit in healthy humans. Aliment Pharmacol Ther. 2012;35(9):1088-1096.
Mark EB, Poulsen JL, Haase A-M, et al. Ambulatory assessment of colonic motility using the electromagnetic capsule tracking system. Neurogastroenterol Motil. 2019;31(2):e13451.
Staahl C, Olesen AE, Andresen T, Arendt-Nielsen L, Drewes AM. Assessing analgesic actions of opioids by experimental pain models in healthy volunteers - An updated review. Br J Clin Pharmacol. 2009;68(2):149-168.
Hartrick C, Van Hove I, Stegmann J-U, Oh C, Upmalis D. Efficacy and tolerability of tapentadol immediate release and oxycodone HCl immediate release in patients awaiting primary joint replacement surgery for end-stage joint disease: a 10-day, phase III, randomized, double-blind, active- and placebo-controlled. Clin Ther. 2009;31(2):260-271.
Lalovic B, Kharasch E, Hoffer C, Risler L, Liu-Chen LY, Shen DD. Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites. Clin Pharmacol Ther. 2006;79(5):461-479.
Terlinden R, Ossig J, Fliegert F, Lange C, Göhler K. Absorption, metabolism, and excretion of 14C-labeled Tapentadol HCl in healthy male subjects. Eur J Drug Metab Pharmacokinet. 2007;32(3):163-169.
Haase AM, Gregersen T, Schlageter V, et al. Pilot study trialling a new ambulatory method for the clinical assessment of regional gastrointestinal transit using multiple electromagnetic capsules. Neurogastroenterol Motil. 2014;26(12):1783-1791.
Mark EB, Frøkjaer JB, Hansen TM, Nedergaard RB, Drewes AM. Although tapentadol and oxycodone both increase colonic volume, tapentadol treatment resulted in softer stools and less constipation: a mechanistic study in healthy volunteers. Scand J Pain. 2021. https://doi.org/10.1515/sjpain-2020-0151
Olesen AE, Drewes AM. Validated tools for evaluating opioid-induced bowel dysfunction. Adv Ther. 2011;28(4):279-294.
Olesen AE, Grønlund D, Mark EB, Krogh K, Frøkjaer JB, Drewes AM. Effects of naloxegol on gastrointestinal transit and colonic fecal volume in healthy participants receiving oxycodone. J Neurogastroenterol Motil. 2019;25(4):602-610.
Sharma SS. Sphincter of Oddi dysfunction in patients addicted to opium: an unrecognized entity. Gastrointest Endosc. 2002;55(3):427-430.
Ono H, Nakamura A, Matsumoto K, Horie S, Sakaguchi G, Kanemasa T. Circular muscle contraction in the mice rectum plays a key role in morphine-induced constipation. Neurogastroenterol Motil. 2014;26(10):1396-1407.
Mark EB, Klinge MW, Grønlund D, et al. Ambulatory assessment of colonic motility using the electromagnetic capsule tracking system: effect of opioids. Neurogastroenterol Motil. 2020;32(3):1-10.
Brock C, Olesen SS, Olesen AE, Frøkjaer JB. Opioid-induced bowel dysfunction pathophysiology and management. Drugs. 2012;72(14):1847-1865.
Galligan JJ, Akbarali HI. Molecular physiology of enteric opioid receptors. Am J Gastroenterol Suppl. 2014;2(1):17-21.
Costa M, Wiklendt L, Simpson P, Spencer NJ, Brookes SJ, Dinning PG. Neuromechanical factors involved in the formation and propulsion of fecal pellets in the guinea-pig colon. Neurogastroenterol Motil. 2015;27(10):1466-1477.
Hans T, Van OL, Sadik R, Abrahamsson H, Jan T, Magnus S. Colonic transit time and IBS symptoms : what's the Link ? Am J Gastroenterol. 2012;107:754-760.
Russo M, Martinelli M, Sciorio E, et al. Stool consistency, but not frequency, correlates with total gastrointestinal transit time. Children. 2013;2-6.
Degen LP, Phillips SF. How well does stool form reflect colonic transit? Gut. 1996;39(1):109-113.
Vijayvargiya P, Jameie-Oskooei S, Camilleri M, Chedid V, Erwin PJ, Murad MH. Association between delayed gastric emptying and upper gastrointestinal symptoms: a systematic review and meta-analysis. Gut. 2019;68(5):804-813.
Gregersen T, Haase A-M, Schlageter V, Gronbaek H, Krogh K. Regional Gastrointestinal transit times in patients with carcinoid diarrhea: assessment with the Novel 3D-transit system. J Neurogastroenterol Motil. 2015;21(3):423-432.
Camilleri M, Thorne NK, Ringel Y, et al. Wireless pH-motility capsule for colonic transit: prospective comparison with radiopaque markers in chronic constipation. Neurogastroenterol Motil. 2010;22(8):874-883.
Poulsen JL, Mark EB, Brock C, Frøkjaer JB, Krogh K, Drewes AM. Colorectal transit and volume during treatment with prolonged-release oxycodone/naloxone versus oxycodone plus macrogol 3350. J Neurogastroenterol Motil. 2018;24(1):119-127.
Poulsen JL, Nilsson M, Brock C, Sandberg TH, Krogh K, Drewes AM. The impact of opioid treatment on regional gastrointestinal transit. J Neurogastroenterol Motil. 2016;22(2):282-291.
Klinge MW, Haase AM, Mark EB, et al. Colonic motility in patients with type 1 diabetes and gastrointestinal symptoms. Neurogastroenterol Motil. 2020;32(12):e13948.
Moore J, Barlow D, Jewell D, Kennedy S. Do gastrointestinal symptoms vary with the menstrual cycle? Br J Obstet Gynaecol. 1998;105(12):1322-1325.